An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.
Sarah Akers
Advertisement
Consultant, Shabas Solutions LLC
Articles by Sarah Akers
Advertisement
Latest Updated Articles
Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for ExecutivesPublished: August 18th 2025 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
2
Former FDA Commissioners Warn New Vaccine Policies Could Undermine Longstanding Regulatory Framework
3
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
4
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
5
